Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin Therapy for Moderate and Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, 40-80 years of age.~2. Clinical diagnosis of at least moderate COPD as defined by the GOLD criteria:~   1. Postbronchodilator FEV1(forced expiratory volume at one second)/FVC(forced vital capacity) \< 70%,~  2. Postbronchodilator FEV1 (forced expiratory volume at one second) \< 80% predicted, with or without chronic symptoms (i.e., cough, sputum production).~3. Cigarette consumption of 10 pack-years or more. Patients may or may not be active smokers.~4. Must meet one or more of the following 4 conditions~   1. Be using supplemental oxygenate~  2. Receiving a course of systemic corticosteroids and/or antibiotics for respiratory problems in the past year,~  3. Visiting an Emergency Department for a COPD exacerbation within the past year, or~  4. Being hospitalized for a COPD (Chronic Obstructive Pulmonary Disease) exacerbation within the past year~5. Willingness to make return visits and availability by telephone for duration of study.~6. Free of active coronary disease~7. Subject with expected life expectancy \> 36 months~Exclusion Criteria:~1. Patients who:~   1. are on statin drugs.~  2. should be on statins based on established risk stratification using the ATP-III (Adult Treatment Panel) to determine 10 year risk.~2. Documented history of active coronary heart disease, such as unstable angina, prior myocardial infarction, stroke, symptomatic peripheral vascular or carotid artery disease, or congestive heart failure within the past 3 months.~3. A diagnosis of asthma.~4. The presence of a diagnosis other than COPD that results in the patient being either medically unstable, or having a predicted life expectancy \< 3 years.~5. Special patient groups: prisoners, pregnant women, institutionalized patients~6. Women who are at risk of becoming pregnant during the study (pre-menopausal) and who refuse to use acceptable birth control (hormone-based oral or barrier contraceptive) for the duration of the study.~7. Woman using estradiol compounds for contraception. Postmenopausal women on estradiol compounds for hormone replacement therapy will be allowed into the trial.~8. Participants otherwise meeting the inclusion criteria will not be enrolled until they are a minimum of four weeks from their most recent acute exacerbation.~9. A clinical diagnosis of bronchiectasis defined as production of \> one-half cup of purulent sputum/day.~10. Participants using niacin, azole antifungals (itraconazole, ketoconazole, posaconazole), fibric acid derivatives, erythromycin, clarithromycin, telithromycin, diltiazem, amlodipine , ranolazine,HIV protease inhibitors (such as indinavir), amiodarone, gemfibrozil, cyclosporine, verapamil, danazol, nefazodone, and red yeast rice extracts are excluded~11. Active liver disease. Active liver disease is defined as ALT (alanine aminotransferase), AST (aspartate aminotransferase) as greater than 1.5 times the upper limit of normal.~12. Patients with renal failure defined by serum creatinine greater than 3mg/dl.~13. Alcoholism. Alcoholism is defined as \> 35 drinks per week. A drink is defined as one bottle of beer, one 8-ounce glass of wine, or one ounce of hard liquor.~14. Hypersensitivity to HMG CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors. Hypersensitivity is defined as an allergic reaction to statin, prior history of myopathy, rhabdomyolysis or previous intolerance to statin use.~15. Participants drinking greater than 4 cups (1qt) of grapefruit juice per day.~16. Participants drinking greater than 3 cups of green tea per day.~17. Diabetics will be excluded. Diabetics are defined by:~1. A CURRENT physician diagnosis of diabetes OR 2. CURRENT use of diabetic meds OR 3. Elevated HbA1c \> 6.5% 18. The discretion of the Principal Investigator that the potential participant will not be a reliable study subject to complete the study requirements.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- simvastatin (Type: ACTIVE_COMPARATOR): 40 mgms of simvastatin daily
- placebo (Type: PLACEBO_COMPARATOR): Matched placebo pill daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy